Larvol Delta - Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Registrational-Phase-2-QUINTESSENTIAL-Trial-of-the-Potential-FirstinClass-GPRC5DDirected-CAR-T-Cell-Therapy-Arlocabtagene-Autoleucel

arlocabtagene autoleucel (BMS-986393) - BMS

https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Registrational-Phase-2-QUINTESSENTIAL-Trial-of-the-Potential-First-in-Class-GPRC5D-Directed-CAR-T-Cell-Therapy-Arlocabtagene-Autoleucel----/default.aspx

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next